Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups.

Gabriella MacchiaAlessia NardangeliConcetta LalisciaAndrei FodorLorena DraghiniPier Carlo GentileGiuseppe Roberto D'AgostinoVittoria BalcetPaolo BonomeMartina FerioliRosa AutorinoLisa VicenziArcangela RagusoSimona BorghesiEdy IppolitoVanessa Di CataldoSavino CillaElisabetta PerrucciMaura CampitelliMaria Antonietta GambacortaFrancesco DeodatoGiovanni ScambiaGabriella Ferrandina

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022)

Our analysis confirmed the efficacy of stereotactic body radiotherapy in oligometastatic/persistent/recurrent cervical cancer patients. The low toxicity profile encourages the wider use of stereotactic body radiotherapy in this setting.

Keyphrases

early stage
locally advanced
radiation induced
radiation therapy
dna damage
oxidative stress
squamous cell carcinoma
dna repair
rectal cancer